High-dose	O
growth	O
hormone	O
does	O
not	O
affect	O
proinflammatory	O
cytokine	I-protein
(	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin-6	B-protein
,	O
and	O
interferon-gamma	B-protein
)	O
release	O
from	O
activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
or	O
after	O
minimal	O
to	O
moderate	O
surgical	O
stress	O
.	O

High-dose	O
GH	O
therapy	O
,	O
with	O
GH	O
doses	O
10-20	O
times	O
the	O
normal	O
replacement	O
dose	O
for	O
GH-deficient	B-protein
adults	O
,	O
has	O
been	O
used	O
as	O
an	O
anti-catabolic	O
agent	O
in	O
a	O
number	O
of	O
different	O
patient	O
groups	O
.	O

A	O
recent	O
study	O
,	O
however	O
,	O
has	O
shown	O
an	O
increase	O
in	O
mortality	O
in	O
critically	O
ill	O
patients	O
treated	O
with	O
high-dose	O
GH	O
.	O

The	O
increased	O
mortality	O
was	O
associated	O
with	O
multiorgan	B-protein
failure	O
,	O
septic	O
shock	O
,	O
and	O
uncontrolled	O
infection	O
,	O
suggesting	O
that	O
GH	O
may	O
have	O
altered	O
the	O
immune	O
response	O
.	O

The	O
GH	O
receptor	I-protein
and	O
GH	O
are	O
both	O
expressed	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
;	O
thus	O
,	O
GH	O
could	O
act	O
as	O
either	O
an	O
endocrine	O
or	O
an	O
autocrine	O
modulator	O
of	O
the	O
immune	O
response	O
.	O

We	O
have	O
examined	O
the	O
hypothesis	O
that	O
high-dose	O
GH	O
therapy	O
may	O
induce	O
proinflammatory	B-protein
cytokines	I-protein
,	O
which	O
are	O
implicated	O
in	O
septic	O
shock	O
.	O

To	O
do	O
this	O
we	O
measured	O
cytokine	B-protein
production	O
by	O
PBMCs	B-cell_type
incubated	O
in	O
conditions	O
that	O
simulated	O
high-dose	O
GH	O
therapy	O
,	O
and	O
we	O
measured	O
cytokine	B-protein
levels	O
in	O
patients	O
undergoing	O
laparoscopic	O
cholecystectomy	O
who	O
were	O
randomized	O
to	O
receive	O
either	O
high-dose	O
GH	O
therapy	O
(	O
13	O
IU/m2	B-protein
x	I-protein
day	O
)	O
or	O
placebo	O
.	O

To	O
confirm	O
the	O
biological	O
activity	O
of	O
GH	O
in	O
our	O
cell	O
culture	O
system	O
we	O
used	O
a	O
Stat5	B-protein
functional	O
assay	O
.	O

In	O
this	O
assay	O
GH	O
induced	O
a	O
bell-shaped	O
curve	O
,	O
with	O
a	O
maximal	O
response	O
at	O
GH	O
levels	O
between	O
100-1	B-protein
,	O
000	I-cell_type
ng/mL	O
.	O

PBMCs	B-cell_type
from	O
healthy	O
volunteers	O
were	O
incubated	O
with	O
GH	O
in	O
doses	O
from	O
1-1	B-cell_type
,	O
000	O
ng/mL	O
for	O
6-72	B-protein
h	O
under	O
resting	O
conditions	O
and	O
after	O
activation	O
with	O
endotoxin	B-protein
and	O
the	O
mixed	O
lymphocyte	O
reaction	O
.	O

Studies	O
were	O
repeated	O
with	O
PBMCs	B-cell_type
from	O
six	O
individuals	O
using	O
a	O
GH	O
dose	O
of	O
100	O
ng/mL	O
(	O
the	O
level	O
of	O
GH	O
found	O
after	O
high-dose	O
GH	O
therapy	O
)	O
and	O
an	O
endotoxin	B-protein
dose	O
that	O
gave	O
a	O
submaximal	O
response	O
(	O
0.01	O
ng/mL	O
)	O
.	O

GH	O
had	O
no	O
effect	O
on	O
cell	O
proliferation	O
or	O
the	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNFalpha	B-protein
)	O
,	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
,	O
or	O
interferon-gamma	B-protein
(	O
IFNgamma	B-protein
)	O
.	O

In	O
patients	O
undergoing	O
laparoscopic	O
cholecystectomy	O
there	O
was	O
a	O
time-related	B-protein
effect	O
of	O
surgery	O
on	O
cytokine	B-protein
levels	O
.	O

There	O
was	O
a	O
rise	O
in	O
IL-6	B-protein
and	O
a	O
fall	O
in	O
TNFalpha	B-protein
at	O
24	O
h	O
after	O
surgery	O
;	O
however	O
,	O
high-dose	O
GH	O
therapy	O
had	O
no	O
effect	O
on	O
the	O
cytokine	B-protein
response	O
.	O

We	O
considered	O
the	O
possibility	O
that	O
endogenous	O
GH	O
production	O
by	O
PBMCs	B-cell_type
could	O
influence	O
the	O
cytokine	B-protein
response	O
in	O
activated	B-cell_type
PBMCs	B-cell_type
;	O
however	O
,	O
incubation	O
of	O
PBMCs	B-cell_type
in	O
the	O
presence	O
of	O
the	O
GH	O
receptor	I-protein
antagonist	O
,	O
B2036	B-protein
,	O
had	O
no	O
effect	O
on	O
TNFalpha	B-protein
,	O
IL-6	B-protein
,	O
or	O
IFNgamma	B-protein
production	O
by	O
PBMCs	B-cell_type
in	O
either	O
the	O
mixed	O
lymphocyte	O
reaction	O
or	O
when	O
activated	O
by	O
endotoxin	B-protein
.	O

These	O
results	O
suggest	O
that	O
high-dose	O
GH	O
therapy	O
does	O
not	O
alter	O
the	O
proinflammatory	B-protein
cytokine	I-protein
response	I-DNA
to	O
surgery	O
or	O
endotoxin	B-protein
.	O

The	O
results	O
do	O
not	O
exclude	O
an	O
effect	O
of	O
GH	O
on	O
the	O
immune	O
response	O
,	O
but	O
they	O
suggest	O
that	O
the	O
mortality	O
seen	O
in	O
critically	O
ill	O
patients	O
may	O
be	O
due	O
to	O
factors	O
other	O
than	O
immune	O
modulation	O
.	O

Interaction	O
between	O
interferon	B-protein
consensus	I-DNA
sequence-binding	I-protein
protein	I-protein
and	O
COP9/signalosome	B-protein
subunit	I-protein
CSN2	B-protein
(	O
Trip15	B-protein
)	O
.	O

A	O
possible	O
link	O
between	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
signaling	O
and	O
the	O
COP9/signalosome	B-protein
.	O

Interferon	B-protein
consensus	I-DNA
sequence-binding	I-protein
protein	I-protein
(	O
ICSBP	B-protein
)	O
is	O
a	O
member	O
of	O
the	O
interferon	B-DNA
regulatory	I-protein
factors	I-protein
(	O
IRF	I-protein
)	I-protein
that	O
has	O
a	O
pivotal	O
role	O
in	O
mediating	O
resistance	O
to	O
pathogenic	O
infections	O
in	O
mice	O
and	O
in	O
promoting	O
the	O
differentiation	O
of	O
myeloid	B-cell_type
cells	I-cell_type
.	O

ICSBP	B-protein
exerts	O
some	O
of	O
its	O
transcriptional	O
activities	O
via	O
association	O
with	O
other	O
factors	O
that	O
enable	O
its	O
binding	O
to	O
a	O
variety	O
of	O
promoters	B-DNA
containing	O
DNA	I-DNA
composite	I-DNA
elements	I-DNA
.	O

These	O
interactions	O
are	O
mediated	O
through	O
a	O
specific	O
COOH-terminal	B-protein
domain	I-protein
termed	O
IAD	B-protein
(	O
IRF	I-protein
association	O
domain	I-protein
)	O
.	O

To	O
gain	O
a	O
broader	O
insight	O
of	O
the	O
capacity	O
of	O
ICSBP	B-protein
to	O
interact	O
with	O
other	O
factors	O
,	O
yeast	O
two-hybrid	O
screens	B-protein
were	O
performed	O
using	O
ICSBP-IAD	B-cell_type
as	O
a	O
bait	O
against	O
a	O
B-cell	B-protein
cDNA	I-DNA
library	I-DNA
.	O

Trip15	O
was	O
identified	O
as	O
a	O
specific	O
interacting	B-protein
factor	I-protein
with	O
ICSBP	B-protein
in	O
yeast	O
cells	I-cell_type
,	O
which	O
was	O
also	O
confirmed	O
by	O
in	O
vitro	O
glutathione	O
S-transferase	O
pull-down	O
assays	O
and	O
by	O
coimmunoprecipitation	O
studies	O
in	O
COS7	B-cell_line
cells	I-cell_type
.	O

Trip15	O
was	O
recently	O
identified	O
as	O
a	O
component	O
of	O
the	O
COP9/signalosome	B-protein
(	O
CSN	B-protein
)	O
complex	I-protein
composed	O
of	O
eight	O
evolutionary	O
conserved	O
subunits	I-protein
and	O
thus	O
termed	O
CSN2	B-protein
.	O

This	O
complex	O
has	O
a	O
role	O
in	O
cell-signaling	B-cell_type
processes	O
,	O
which	O
is	O
manifested	O
by	O
its	O
associated	O
novel	O
kinase	I-protein
activity	O
and	O
by	O
the	O
involvement	O
of	O
its	O
subunits	O
in	O
regulating	O
multiple	O
cell-signaling	I-cell_line
pathways	O
and	O
cell-cycle	O
progression	O
.	O

We	O
show	O
that	O
in	O
vitro	O
association	O
of	O
ICSBP	B-protein
with	O
the	O
CSN	B-protein
leads	O
to	O
phosphorylation	O
of	O
ICSBP	B-protein
at	O
a	O
unique	O
serine	O
residue	O
within	O
its	O
IAD	B-protein
.	O

The	O
phosphorylated	O
residue	O
is	O
essential	O
for	O
efficient	O
association	O
with	O
IRF-1	B-protein
and	O
thus	O
for	O
the	O
repressor	O
activity	O
of	O
ICSBP	B-protein
exerted	O
on	O
IRF-1	B-protein
.	O

This	O
suggests	O
that	O
the	O
CSN	B-protein
has	O
a	O
role	O
in	O
integrating	O
incoming	O
signals	O
that	O
affect	O
the	O
transcriptional	O
activity	O
of	O
ICSBP	B-protein
.	O

Intrathymic	O
T	I-cell_type
cell	O
development	O
and	O
selection	O
proceeds	O
normally	O
in	O
the	O
absence	O
of	O
glucocorticoid	B-protein
receptor	I-protein
signaling	O
.	O

Glucocorticoids	O
are	O
believed	O
to	O
play	O
a	O
role	O
in	O
T	B-cell_type
cell	O
development	O
and	O
selection	O
,	O
although	O
their	O
precise	O
function	O
is	O
controversial	O
.	O

Glucocorticoid	O
receptor	I-protein
(	O
GR	B-protein
)	O
-deficient	O
mice	O
were	O
used	O
to	O
directly	O
investigate	O
this	O
problem	O
.	O

GR-deficient	O
thymocytes	I-cell_type
were	O
resistant	O
to	O
dexamethasone-mediated	O
apoptosis	O
,	O
confirming	O
the	O
absence	O
of	O
glucocorticoid	B-protein
responsiveness	O
.	O

An	O
absence	O
of	O
GR	B-protein
signaling	O
had	O
no	O
impact	O
on	O
thymocyte	B-cell_type
development	O
either	O
in	O
vivo	O
or	O
in	O
vitro	O
.	O

T	B-cell_type
cell	O
differentiation	O
,	O
including	O
positive	O
selection	O
,	O
was	O
normal	O
as	O
assessed	O
by	O
normal	B-cell_type
development	O
of	O
CD4+CD8+	B-protein
,	O
alphabetaTCR+CD4+	B-protein
,	O
and	O
alphabetaTCR+CD8+	B-protein
thymocytes	I-cell_type
.	O

Negative	O
selection	O
,	O
mediated	O
by	O
the	O
superantigen	B-protein
staphylococcal	B-protein
enterotoxin	I-protein
B	I-protein
(	O
SEB	B-protein
)	O
,	O
or	O
anti-CD3/CD28	B-protein
,	O
was	O
also	O
normal	O
in	O
the	O
absence	O
of	O
GR	B-protein
signaling	O
.	O

In	O
contrast	O
to	O
earlier	O
reports	O
,	O
these	O
data	O
demonstrate	O
that	O
GR	B-protein
signaling	O
is	O
not	O
essential	O
for	O
intrathymic	O
T	O
cell	O
development	O
or	O
selection	O
.	O

Rapid	O
polarization	O
of	O
Th2	B-cell_type
cells	I-cell_type
during	O
induction	O
of	O
antigen-specific	O
IgE	B-protein
antibodies	I-protein
in	O
vitro	O
.	O

BACKGROUND	O
:	O
Type	B-protein
2	O
T-helper	O
cells	I-cell_type
(	O
Th2	O
)	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
humoral	O
immune	O
response	O
against	O
antigens	O
and	O
allergens	B-protein
and	O
directly	O
affect	O
which	O
isotype	O
will	O
be	O
produced	O
.	O

The	O
mechanism	O
that	O
regulates	O
antigen-specific	O
IgE	B-protein
secretion	O
and	O
immune	O
deviation	O
is	O
still	O
not	O
known	O
.	O

OBJECTIVES	O
:	O
To	O
delineate	O
mechanisms	O
behind	O
antigen-specific	O
IgE	B-protein
secretion	O
we	O
have	O
used	O
in	O
vitro	O
immunization	O
and	O
focused	O
on	O
T-cell	B-protein
phenotype	O
and	O
the	O
activation	O
status	O
of	O
the	O
transcription	B-protein
factor	I-protein
NFkappaB	B-protein
.	O

METHODS	O
:	O
Peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBMC	B-cell_type
)	O
from	O
seronegative	B-cell_type
donors	O
were	O
immunized	O
in	O
vitro	O
with	O
a	O
peptide	O
consisting	O
of	O
both	O
a	O
T-cell	B-protein
and	O
a	O
B-cell	B-cell_line
epitope	I-DNA
.	O

RESULTS	O
:	O
Antigen-specific	O
IgE	B-protein
antibodies	I-protein
could	O
be	O
detected	O
after	O
a	O
primary	O
immunization	O
,	O
during	O
which	O
T-helper	O
cells	O
secreted	O
type	O
2	O
cytokines	B-protein
.	O

Specific	O
IgE	B-protein
was	O
also	O
detected	O
in	O
the	O
secondary	O
immunization	O
,	O
but	O
due	O
to	O
a	O
rapid	O
polarization	O
from	O
Th2	B-cell_type
to	O
Th1	B-cell_type
phenotype	O
,	O
exogenous	O
IL-4	B-protein
was	O
required	O
for	O
the	O
specific	O
IgE	B-protein
secretion	O
.	O

Analysis	O
of	O
NFkappaB	B-protein
activation	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
during	O
primary	O
and	O
secondary	O
immunization	O
showed	O
that	O
NFkappaB	B-protein
could	O
be	O
detected	O
in	O
both	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
during	O
primary	O
immunization	O
,	O
but	O
was	O
dependent	O
on	O
exogenous	O
IL-4	B-protein
in	O
the	O
secondary	O
immunization	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
evidence	O
of	O
antigen-specific	O
IgE	B-protein
induction	O
in	O
vitro	O
using	O
naive	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
demonstrating	O
the	O
involvement	O
of	O
T-helper	B-cell_type
cell	I-cell_line
phenotype	I-cell_type
and	O
NFkappaB	B-protein
and	O
demonstrates	O
the	O
usefulness	O
of	O
in	O
vitro	O
cultures	I-cell_line
to	O
study	O
the	O
effect	O
of	O
antigens	B-protein
on	O
human	B-cell_type
immunocytes	I-protein
.	O

Pulmonary	O
function	O
changes	O
and	O
increased	O
Th-2	O
cytokine	I-protein
expression	O
and	O
nuclear	B-protein
factor	I-protein
kB	I-protein
activation	O
in	O
the	O
lung	O
after	O
sensitization	O
and	O
allergen	O
challenge	O
in	O
brown	B-cell_type
Norway	I-cell_type
rats	O
.	O

BACKGROUND	O
:	O
Our	O
purpose	O
was	O
to	O
evaluate	O
the	O
expression	O
of	O
Th-1	B-protein
and	O
Th-2	B-protein
related	O
cytokine	B-protein
mRNA	I-RNA
and	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
kB	I-protein
in	O
the	O
lung	O
tissue	O
of	O
ovalbumin	B-protein
(	O
OA	B-protein
)	O
sensitized	I-cell_type
brown	I-cell_line
Norway	I-cell_line
rats	O
(	O
BNR	O
)	O
.	O

We	O
also	O
evaluated	O
the	O
correlation	O
between	O
bronchial	O
hyperreactivity	O
(	O
BHR	B-protein
)	O
and	O
eosinophils	B-cell_type
with	O
cytokine	B-protein
mRNA	I-RNA
expression	O
.	O

METHODS	O
:	O
Eight	O
BNR	B-protein
(	O
weight	O
range	O
250-350	B-protein
g	O
)	O
were	O
sensitized	O
by	O
inhaled	O
OA	B-protein
(	O
group	O
I	I-protein
)	I-protein
with	O
a	O
1-week	B-protein
interval	O
between	O
and	O
then	O
provoked	O
with	O
OA	B-protein
1	I-protein
week	O
later	O
.	O

Pulmonary	O
function	O
tests	O
(	O
PFT	O
)	O
were	O
performed	O
at	O
baseline	O
and	O
24	O
h	O
after	O
acetylcholine	O
challenge	O
.	O

Eight	O
weight-matched	B-protein
normal	O
BNR	O
served	O
as	O
controls	O
(	O
group	O
II	O
)	O
.	O

All	O
animals	O
were	O
anesthetized	O
,	O
paralyzed	B-protein
with	O
gallamine	B-protein
,	O
and	O
ventilated	O
via	O
tracheostomy	B-protein
.	O

They	O
were	O
given	O
varying	O
doses	O
of	O
acetylcholine	B-protein
(	O
25	O
,	O
50	O
,	O
75	O
,	O
100	O
microg/kg	O
)	O
injected	O
through	O
a	O
jugular	B-protein
venous	O
catheter	B-protein
.	O

Five	O
seconds	O
after	O
acetylcholine	O
injections	O
,	O
PFTs	B-protein
were	O
performed	O
,	O
including	O
a	O
maximal	O
forced	O
expiratory	I-DNA
maneuver	I-DNA
(	O
MFEM	B-protein
)	O
,	O
airway	O
opening	O
pressure	O
(	O
P	O
(	O
ao	B-protein
)	O
)	O
at	O
tidal	O
breathing	B-protein
and	O
total	O
dynamic	O
lung	O
compliance	B-protein
(	O
C	O
(	O
dyn	B-protein
)	O
)	O
.	O

Bronchoalveolar	B-cell_type
lavage	I-cell_type
(	I-cell_type
BAL	I-cell_type
)	O
was	O
then	O
performed	O
with	O
20	O
ml	O
normal	O
saline	O
divided	O
into	O
two	O
doses	O
.	O

Thereafter	O
,	O
the	O
lungs	O
were	O
removed	O
and	O
examined	O
histologically	B-protein
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
lung	O
tissue	O
samples	O
and	O
reverse-transcriptase	O
polymerase	O
chain	O
reaction	O
was	O
performed	O
using	O
primers	O
for	O
mRNA	B-RNA
of	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-10	B-protein
,	O
interferon-gamma	B-protein
(	O
IFNr	B-protein
)	O
and	O
beta-actine	B-protein
.	O

RESULTS	O
:	O
Group	O
I	B-protein
OA	B-protein
treated	I-protein
rats	I-protein
had	O
typical	O
airway	O
obstruction	O
on	O
PFTs	B-cell_type
and	O
airway	O
inflammation	O
on	O
histological	O
examination	O
.	O

Ratios	O
of	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-10	B-protein
and	O
inducible	O
nitric	O
oxide	I-protein
synthase	I-protein
(	O
iNOS	B-protein
)	O
mRNA	I-RNA
levels	O
to	O
beta-actine	B-protein
as	O
measured	O
by	O
densitometry	O
were	O
significantly	O
lower	O
in	O
controls	O
than	O
in	O
OA-sensitized	B-cell_type
rats	O
.	O

The	O
IFNr	B-protein
mRNA	I-RNA
to	O
beta-actin	B-protein
ratio	O
was	O
significantly	O
reduced	O
in	O
OA-sensitized	B-cell_type
rats	O
.	O

Group	O
I	B-protein
demonstrated	O
a	O
band	O
shift	O
when	O
compared	O
with	O
group	O
II	O
in	O
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
for	O
NF-kB	B-protein
indicating	O
increased	O
activation	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O

CONCLUSION	O
:	O
Th-2	O
related	O
cytokine	B-protein
mRNA	I-RNA
was	O
increased	O
but	O
Th-1	O
related	O
cytokine	B-protein
mRNA	I-RNA
was	O
decreased	O
in	O
OA-sensitized	B-cell_type
BNR	I-cell_type
.	O

An	O
increased	O
level	O
of	O
Th-2	B-protein
related	O
cytokine	B-protein
mRNA	I-RNA
correlated	O
with	O
decreased	O
airflow	O
and	O
inflammatory	O
changes	O
.	O

These	O
results	O
demonstrate	O
the	O
value	O
of	O
the	O
BNR	B-protein
model	O
for	O
studying	O
allergic	O
asthma	O
at	O
the	O
molecular	O
level	O
.	O

3	O
,	O
5-Bis	B-protein
(	O
trifluoromethyl	B-protein
)	O
pyrazoles	O
:	O
a	O
novel	O
class	B-DNA
of	O
NFAT	B-protein
transcription	I-protein
factor	I-protein
regulator	I-protein
.	O

A	O
series	O
of	O
bis	O
(	O
trifluoromethyl	B-protein
)	O
pyrazoles	I-cell_line
(	O
BTPs	B-protein
)	O
has	O
been	O
found	O
to	O
be	O
a	O
novel	O
inhibitor	O
of	O
cytokine	B-protein
production	O
.	O

Identified	O
initially	O
as	O
inhibitors	O
of	O
IL-2	B-protein
synthesis	O
,	O
the	O
BTPs	B-protein
have	O
been	O
optimized	O
in	O
this	O
regard	O
and	O
even	O
inhibit	O
IL-2	B-protein
production	O
with	O
a	O
10-fold	O
enhancement	O
over	O
cyclosporine	O
in	O
an	O
ex	O
vivo	O
assay	O
.	O

Additionally	O
,	O
the	O
BTPs	B-protein
show	O
inhibition	O
of	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-8	B-protein
,	O
and	O
eotaxin	B-DNA
production	O
.	O

Unlike	O
the	O
IL-2	B-DNA
inhibitors	O
,	O
cyclosporine	O
and	O
FK506	O
,	O
the	O
BTPs	B-protein
do	O
not	O
directly	O
inhibit	O
the	O
dephosphorylation	O
of	O
NFAT	B-protein
by	O
calcineurin	B-protein
.	O

A	O
repression-derepression	B-DNA
mechanism	O
regulating	O
the	O
transcription	B-protein
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	I-DNA
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

BACKGROUND	O
:	O
Despite	O
some	O
controversy	O
regarding	O
the	O
preferential	O
infection	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	I-DNA
(	O
HIV-1	I-DNA
)	O
,	O
it	O
appears	O
that	O
primary	O
T	I-cell_type
lymphocytes	I-cell_type
,	O
in	O
their	O
quiescent	O
state	O
,	O
are	O
nonpermissive	O
for	O
viral	O
expression	O
and	O
propagation	O
.	O

Massive	O
activation	O
of	O
viral	O
gene	I-DNA
expression	O
occurs	O
only	O
when	O
the	O
host	O
lymphocyte	O
is	O
activated	O
.	O

These	O
observations	O
prompted	O
us	O
to	O
investigate	O
the	O
transcriptional	O
regulation	O
of	O
HIV-1	O
in	O
resting	B-cell_type
or	I-cell_type
activated	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
were	O
isolated	O
from	O
cord	B-cell_type
blood	I-cell_type
or	O
adult	O
peripheral	I-cell_type
blood	I-cell_type
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
To	O
this	O
end	O
,	O
we	O
employed	O
cellular	O
purification	O
and	O
phenotyping	O
techniques	O
,	O
in	O
vitro	O
protein-DNA	O
binding	O
studies	O
,	O
functional	O
transactivation	O
assays	O
using	O
proteins	O
isolated	O
from	O
cord	I-cell_type
blood	I-cell_type
or	O
adult	O
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
and	O
transfection	O
experiments	O
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

RESULTS	O
:	O
We	O
showed	O
that	O
transcription	B-protein
from	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
is	O
repressed	O
in	O
resting	B-cell_type
naive	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
;	O
whereas	O
,	O
mitogenically	O
stimulated	O
CD4+	O
cells	I-cell_type
form	O
an	O
activator	B-protein
that	O
derepresses	B-protein
transcription	O
.	O

Negative	O
and	O
positive	O
regulation	O
act	O
through	O
a	O
repressor-activator	B-protein
target	I-DNA
sequence	I-DNA
(	O
RATS	B-protein
)	O
,	O
which	O
shares	O
homology	O
with	O
the	O
interleukin-2	B-DNA
(	O
IL-2	B-protein
)	O
purine-rich	I-DNA
response	I-DNA
element	I-DNA
,	O
through	O
the	O
adjacent	B-DNA
binding	I-DNA
site	I-DNA
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-cell_type
(	O
NFAT	B-protein
)	O
,	O
and	O
weakly	O
,	O
through	O
the	O
KB	B-protein
region	I-DNA
.	O

CONCLUSIONS	O
:	O
This	O
regulation	O
exerted	O
by	O
cellular	O
transcription	I-protein
factors	I-protein
can	O
account	O
for	O
several	O
important	O
features	O
of	O
HIV-1	O
expression	O
in	O
primary	B-cell_type
CD4+	I-cell_type
cells	I-cell_type
.	O

Tight	O
repression	O
in	O
resting	B-cell_type
naive	I-cell_type
T	I-cell_type
helper	I-cell_type
cells	I-cell_type
may	O
be	O
a	O
main	O
cause	O
of	O
viral	O
latency	O
and	O
transcriptional	O
activation	O
accounts	O
for	O
massive	O
viral	O
production	O
in	O
activated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Involvement	O
of	O
lipopolysaccharide	O
binding	O
protein	I-protein
,	O
CD14	B-protein
,	O
and	O
Toll-like	B-protein
receptors	I-protein
in	O
the	O
initiation	O
of	O
innate	O
immune	O
responses	O
by	O
Treponema	O
glycolipids	B-protein
.	O

Culture	O
supernatants	O
from	O
Treponema	O
maltophilum	B-protein
associated	O
with	O
periodontitis	O
in	O
humans	O
and	O
Treponema	O
brennaborense	B-protein
found	O
in	O
a	O
bovine	O
cattle	I-protein
disease	O
accompanied	O
with	O
cachexia	O
caused	O
a	O
dose-dependent	O
TNF-alpha	B-protein
synthesis	O
in	O
human	B-cell_type
monocytes	I-cell_type
increasing	O
with	O
culture	O
time	O
.	O

This	O
activity	O
could	O
be	O
reduced	O
significantly	O
by	O
blocking	O
the	O
CD14	B-protein
-part	B-protein
of	O
the	O
LPS	O
receptor	I-protein
using	O
the	O
My	B-protein
4	I-DNA
mAb	I-protein
and	O
by	O
polymyxin	O
B	O
.	O

In	O
the	O
murine	B-DNA
macrophage	I-DNA
cell	I-cell_line
line	I-cell_line
RAW	I-cell_line
264.7	I-cell_line
,	O
Treponema	O
culture	O
supernatants	O
induced	O
TNF-alpha	B-protein
secretion	O
in	O
a	O
LPS	O
binding	O
protein	I-protein
(	O
LBP	O
)	O
-dependent	O
fashion	O
.	O

To	O
enrich	B-protein
for	O
active	O
compounds	O
,	O
supernatants	O
were	O
extracted	O
with	O
butanol	B-protein
,	O
while	O
whole	O
cells	I-cell_type
were	O
extracted	O
using	O
a	O
phenol/water	B-protein
method	O
resulting	O
in	O
recovery	O
of	O
material	O
exhibiting	O
a	O
similar	O
activity	O
profile	O
.	O

An	O
LPS-LBP	B-protein
binding	I-protein
competition	O
assay	O
revealed	O
an	O
interaction	O
of	O
the	O
treponeme	B-protein
phenol/water	I-protein
extracts	O
with	O
LBP	O
,	O
while	O
precipitation	O
studies	O
implied	O
an	O
affinity	O
to	O
polymyxin	O
B	B-DNA
and	O
endotoxin	B-protein
neutralizing	O
protein	I-protein
.	O

Macrophages	B-cell_type
obtained	O
from	O
C3H/HeJ	O
mice	O
carrying	O
a	O
Toll-like	B-protein
receptor	I-protein
(	O
TLR	I-protein
)	O
-4	I-protein
mutation	O
were	O
stimulated	O
with	O
treponeme	B-protein
extracts	O
for	O
NO	O
release	O
to	O
assess	O
the	O
role	O
of	O
TLRs	B-protein
in	O
cell	O
activation	O
.	O

Furthermore	O
,	O
NF-kappaB	B-protein
translocation	O
in	O
TLR-2-negative	B-cell_type
Chinese	O
hamster	I-cell_type
ovary	I-cell_type
(	O
CHO	I-cell_type
)	O
cells	I-cell_type
was	O
studied	O
.	O

We	O
found	O
that	O
phenol/water-extracts	B-protein
of	O
the	O
two	O
strains	O
use	O
TLRs	O
differently	O
with	O
T.	B-cell_type
brennaborense-stimulating	I-protein
cells	I-cell_type
in	O
a	O
TLR-4-dependent	O
fashion	O
,	O
while	O
T.	B-cell_type
maltophilum-mediated	I-cell_type
activation	O
apparently	O
involved	O
TLR-2	O
.	O

These	O
results	O
indicate	O
the	O
presence	O
of	O
a	O
novel	O
class	B-DNA
of	O
glycolipids	B-protein
in	O
Treponema	B-cell_type
initiating	O
inflammatory	O
responses	O
involving	O
LBP	O
,	O
CD14	B-protein
,	O
and	O
TLRs	B-protein
.	O

Integration	O
of	O
calcineurin	B-protein
and	O
MEF2	B-protein
signals	O
by	O
the	O
coactivator	B-protein
p300	I-protein
during	O
T-cell	O
apoptosis	O
.	O

T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
-induced	O
thymocyte	O
apoptosis	O
is	O
mediated	O
by	O
calcium-dependent	B-protein
signal	O
transduction	O
pathways	O
leading	O
to	O
the	O
transcriptional	O
activation	O
of	O
members	O
of	O
the	O
Nur77	B-protein
family	I-protein
.	O

The	O
major	O
calcium-	B-DNA
and	O
calcineurin-responsive	B-protein
elements	I-DNA
in	O
the	O
Nur77	B-protein
promoter	I-DNA
are	O
binding	O
sites	I-protein
for	O
myocyte	B-protein
enhancer	I-DNA
factor-2	I-protein
(	O
MEF2	I-protein
)	I-protein
.	O

It	O
has	O
been	O
shown	O
that	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-cell_type
(	O
NFAT	B-protein
)	O
interacts	O
with	O
MEF2D	B-protein
and	O
enhances	O
its	O
transcriptional	O
activity	O
,	O
offering	B-protein
a	O
plausible	O
mechanism	O
of	O
activation	O
of	O
MEF2D	B-protein
by	O
calcineurin	B-protein
.	O

We	O
report	O
here	O
that	O
NFATp	B-protein
synergizes	O
with	O
MEF2D	B-protein
to	O
recruit	O
the	O
coactivator	B-protein
p300	I-protein
for	O
the	O
transcription	B-protein
of	O
Nur77	B-protein
.	O

Surprisingly	O
,	O
the	O
enhancement	O
of	O
transcriptional	O
activity	O
of	O
MEF2D	B-protein
by	O
NFATp	B-protein
does	O
not	O
require	O
its	O
DNA-binding	B-protein
activity	O
,	O
suggesting	O
that	O
NFATp	B-protein
acts	O
as	O
a	O
coactivator	B-protein
for	O
MEF2D	B-protein
.	O

Transient	O
co-expression	O
of	O
p300	B-protein
,	O
MEF2D	B-protein
,	O
NFATp	B-protein
and	O
constitutively	O
active	O
calcineurin	B-protein
is	O
sufficient	O
to	O
recapitulate	O
TCR	B-protein
signaling	O
for	O
the	O
selective	O
induction	O
of	O
the	O
endogenous	B-DNA
Nur77	I-protein
gene	I-DNA
.	O

These	O
results	O
implicate	O
NFAT	B-protein
as	O
an	O
important	O
mediator	O
of	O
T-cell	B-protein
apoptosis	O
and	O
suggest	O
that	O
NFAT	B-protein
is	O
capable	O
of	O
integrating	O
the	O
calcineurin	B-protein
signaling	O
pathway	O
and	O
other	O
pathways	O
through	O
direct	O
protein-protein	O
interaction	O
with	O
other	O
transcription	B-protein
factors	I-protein
.	O

Induction	O
or	O
suppression	O
of	O
a	O
B	B-protein
cell-specific	I-DNA
response	I-DNA
to	O
self	O
antigen	I-protein
in	O
vivo	O
is	O
dependent	O
upon	O
dendritic	O
cell	O
activation	O
via	O
the	O
TNF-alpha	B-DNA
receptor	I-protein
at	O
the	O
time	O
of	O
antigen	O
uptake	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
the	O
retinal	B-protein
autoantigen	I-protein
,	O
S-antigen	B-protein
,	O
contains	O
a	O
functional	O
TNF-alpha	B-DNA
homologous	O
domain	I-protein
which	O
stimulates	O
maturation	O
and	O
differentiation	O
of	O
cultured	B-cell_line
dendritic	I-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
or	O
tissue	O
DC	I-cell_type
via	O
the	O
p55	B-protein
TNF-alpha	B-protein
receptor	I-protein
.	O

Tissue	O
DC	B-cell_type
became	O
more	O
dendritiform	B-protein
in	O
shape	O
,	O
and	O
migrated	O
into	O
culture	O
supernatant	O
.	O

S-antigen	O
also	O
stimulated	O
accumulation	O
of	O
cell	O
surface	O
MHC	B-protein
class	I-protein
II	I-protein
antigen	I-protein
with	O
a	O
corresponding	O
loss	O
of	O
acidic	B-protein
intracellular	I-protein
vesicles	O
,	O
and	O
induced	O
IL-1beta	B-protein
and	O
IL-12	B-protein
mRNA	I-RNA
expression	O
in	O
cultured	B-cell_line
bone	I-cell_type
marrow-derived	I-cell_type
DC	I-cell_type
.	O

In	O
addition	O
,	O
cultured	B-cell_line
splenic	I-cell_line
DC	I-cell_type
primed	O
immune	O
responses	O
to	O
S-antigen	B-protein
in	O
vivo	O
in	O
the	O
absence	O
of	O
other	O
,	O
exogenous	O
cytokine	I-protein
sources	O
.	O

DC	B-cell_type
pulsed	O
with	O
either	O
retinal	B-protein
S-antigen	B-protein
or	O
another	O
retinal	B-protein
autoantigen	I-protein
,	O
interphotoreceptor	B-protein
retinoid	I-protein
binding	I-protein
protein	I-protein
(	O
IRBP	B-protein
)	O
,	O
were	O
able	O
to	O
stimulate	O
naive	B-cell_type
T	I-cell_type
cell	O
proliferation	O
in	O
vitro	O
,	O
but	O
only	O
S-antigen	B-protein
-pulsed	B-protein
DC	I-cell_type
were	O
able	O
to	O
induce	O
an	O
immune	O
response	O
in	O
vivo	O
and	O
initiate	O
antibody	O
class	I-protein
switching	O
.	O

In	O
contrast	O
,	O
IRBP	O
-pulsed	I-cell_type
DC	I-cell_type
had	O
no	O
detectable	O
in	O
vivo	O
priming	O
effect	O
and	O
IgG	B-protein
antibody	I-protein
levels	O
remained	O
suppressed	O
even	O
after	O
immunization	O
with	O
IRBP	B-protein
in	O
complete	O
Freund	O
's	O
adjuvant	O
.	O

These	O
results	O
indicate	O
that	O
DC	B-cell_type
from	O
the	O
same	O
precursor	B-cell_type
population	O
can	O
either	O
induce	O
or	O
suppress	O
a	O
B	O
cell-specific	I-DNA
response	I-DNA
to	O
self	O
antigen	I-protein
in	O
vivo	O
,	O
the	O
outcome	O
being	O
dependent	O
upon	O
DC	B-cell_type
activation	O
at	O
the	O
time	O
of	O
antigen	O
uptake	O

